Kimura T, Fujiyama Y, Sasaki M, Andoh A, Fukuda M, Nakajima S, Bamba T
Department of Internal Medicine, Shiga University of Medical Science, Tukinowa, Otsu, Japan.
Eur J Gastroenterol Hepatol. 1998 Aug;10(8):659-66.
In this study, we determined the role of mucosal mast cell (MMC) activation in the pathogenesis of intestinal ischaemia-reperfusion (I/R) injury by immunohistochemical analysis using anti-RMCP II antibody. In addition, we investigated the role of free-radical generation in the activation of MMCs in this model.
In the first experiment, rats were divided into four groups: (1) sham operated; (2) I/R + saline; (3) I/R + the mast cell stabilizer, MAR-99 (30 mg/kg); and (4) I/R + MAR-99 (100 mg/kg). Treatment with MAR-99 was started 1 h before the occlusion of the superior mesenteric artery (SMA). In the second experiment, rats were divided into five groups: (1) sham operated; (2) I/R + saline; (3) I/R + superoxide dismutase (SOD; 50,000 U/ml); (4) I/R + catalase (90,000 U/ml); and (5) I/R + allopurinol (50 mg/kg/day). Intravenous administration of SOD and catalase was performed 1 h before SMA occlusion. Oral administration of allopurinol was started 2 days before I/R surgery. We measured several parameters of intestinal mucosal injury and evaluated the degranulation of MMCs by using an immunohistochemical technique.
The number of resting MMCs, detected by anti-RMCP II antibody, was significantly decreased in the I/R-treated rats. The I/R treatment induced a decrease in the mucosal histamine content and an increase in plasma histamine levels. Mucosal permeability in the small intestine was significantly enhanced by I/R treatment. However, these changes were significantly prevented by pretreatment with the MMC stabilizer, MAR-99. Furthermore, administration of several free-radicals scavengers (SOD, catalase, and allopurinol) also blocked the I/R-induced degranulation of MMCs.
These data indicate that activation of MMCs was involved in the pathogenesis of I/R-induced intestinal mucosal injury. In addition, some parts of the I/R-induced MMC activation pathway were mediated by free-radical generation.
在本研究中,我们通过使用抗RMCP II抗体的免疫组织化学分析,确定黏膜肥大细胞(MMC)激活在肠缺血再灌注(I/R)损伤发病机制中的作用。此外,我们研究了自由基生成在该模型中MMC激活中的作用。
在第一个实验中,将大鼠分为四组:(1)假手术组;(2)I/R + 生理盐水组;(3)I/R + 肥大细胞稳定剂MAR-99(30 mg/kg)组;(4)I/R + MAR-99(100 mg/kg)组。在肠系膜上动脉(SMA)闭塞前1小时开始用MAR-99治疗。在第二个实验中,将大鼠分为五组:(1)假手术组;(2)I/R + 生理盐水组;(3)I/R + 超氧化物歧化酶(SOD;50,000 U/ml)组;(4)I/R + 过氧化氢酶(90,000 U/ml)组;(5)I/R + 别嘌呤醇(50 mg/kg/天)组。在SMA闭塞前1小时静脉注射SOD和过氧化氢酶。在I/R手术前2天开始口服别嘌呤醇。我们测量了肠黏膜损伤的几个参数,并使用免疫组织化学技术评估了MMC的脱颗粒情况。
通过抗RMCP II抗体检测到,I/R处理的大鼠中静息MMC的数量显著减少。I/R处理导致黏膜组胺含量降低,血浆组胺水平升高。I/R处理显著增强了小肠黏膜通透性。然而,用MMC稳定剂MAR-99预处理可显著预防这些变化。此外,给予几种自由基清除剂(SOD、过氧化氢酶和别嘌呤醇)也可阻断I/R诱导的MMC脱颗粒。
这些数据表明MMC激活参与了I/R诱导的肠黏膜损伤的发病机制。此外,I/R诱导的MMC激活途径的某些部分是由自由基生成介导的。